Skip to content

SIGYN THERAPEUTICS, INC.: 10-Q filed 2024-11-19

What SIGYN THERAPEUTICS, INC. reported in its quarterly report filed 2024-11-19 (fiscal Q3 2024): 34 published measures, 100 facts as tagged in accession 0001493152-24-046847.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-19
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-046847 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SIGYN THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-30427,438USD
At 2023-12-31321,806USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-304,350,024USD
At 2023-12-313,734,306USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-30-3,922,586USD
At 2024-06-30-3,672,141USD
At 2024-03-31-4,021,254USD
At 2023-12-31-3,412,500USD
At 2023-09-30-3,575,671USD
At 2023-06-30-3,042,218USD
At 2023-03-31-2,346,038USD
At 2022-12-31-1,903,240USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-30164,788USD
At 2023-12-3111,690USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,196,923USD92
2024-01-01 to 2024-09-30-2,817,394USD274
2024-04-01 to 2024-06-30-862,383USD91
2024-01-01 to 2024-03-31-758,088USD91
2023-07-01 to 2023-09-30-905,726USD92
2023-01-01 to 2023-09-30-2,969,886USD273
2023-04-01 to 2023-06-30-723,124USD91
2023-01-01 to 2023-03-31-1,341,036USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-582,218USD274
2023-01-01 to 2023-09-30-1,255,316USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-30735,316USD274
2023-01-01 to 2023-09-301,311,544USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-14,158,906USD
At 2023-12-31-11,341,512USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,268,795shares92
2024-01-01 to 2024-09-301,245,885shares274
2023-07-01 to 2023-09-301,105,844shares92
2023-01-01 to 2023-09-301,050,782shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,268,795shares92
2024-01-01 to 2024-09-301,245,885shares274
2023-07-01 to 2023-09-301,105,844shares92
2023-01-01 to 2023-09-301,050,782shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.94USD/shares92
2024-01-01 to 2024-09-30-2.26USD/shares274
2023-07-01 to 2023-09-30-0.82USD/shares92
2023-01-01 to 2023-09-30-2.83USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.94USD/shares92
2024-01-01 to 2024-09-30-2.26USD/shares274
2023-07-01 to 2023-09-30-0.82USD/shares92
2023-01-01 to 2023-09-30-2.83USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-3011,048USD
At 2023-12-3115,296USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-09-30112,500USD274
2023-01-01 to 2023-09-30112,500USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-808,458USD92
2024-01-01 to 2024-09-30-2,041,232USD274
2023-07-01 to 2023-09-30-642,814USD92
2023-01-01 to 2023-09-30-1,738,081USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-30269,108USD
At 2023-12-31118,063USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-304,275,276USD
At 2023-12-313,608,004USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-30611,643USD
At 2023-12-31461,646USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-30808,458USD92
2024-01-01 to 2024-09-302,041,232USD274
2023-07-01 to 2023-09-30642,814USD92
2023-01-01 to 2023-09-301,738,081USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-3050,000USD
At 2023-12-3150,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-30206,161USD92
2024-01-01 to 2024-09-30679,183USD274
2023-07-01 to 2023-09-30215,230USD92
2023-01-01 to 2023-09-30582,232USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-301,420,678shares
At 2023-12-311,288,415shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3010,236,178USD
At 2023-12-317,928,883USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-09-30126,571USD
At 2023-12-31167,736USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-09-30142,398USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2024-09-301,995,588USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-3021,150USD
At 2023-12-3116,902USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-09-3020,711USD
At 2023-12-3120,711USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,196,923USD92
2024-01-01 to 2024-09-30-2,817,394USD274
2023-07-01 to 2023-09-30-905,726USD92
2023-01-01 to 2023-09-30-2,969,886USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30564,683USD92
2024-01-01 to 2024-09-301,249,089USD274
2023-07-01 to 2023-09-30390,033USD92
2023-01-01 to 2023-09-301,043,014USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,363USD92
2024-01-01 to 2024-09-304,248USD274
2023-07-01 to 2023-09-301,716USD92
2023-01-01 to 2023-09-305,146USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-388,465USD92
2024-01-01 to 2024-09-30-776,162USD274
2023-07-01 to 2023-09-30-262,912USD92
2023-01-01 to 2023-09-30-1,231,805USD273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-01-01 to 2024-09-3057,619USD274
2023-01-01 to 2023-09-3055,941USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30149,997USD274
2023-01-01 to 2023-09-3034,112USD273

Inspect the source

Entity
SIGYN THERAPEUTICS, INC. / CIK 0001642159
Captured
2026-09-21T17:22:56.950Z
SEC response SHA-256
e0e4d7f4bb391730e2aba50a78fbec4c845e6f42106fcbd8cdabccf8b438da5e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001642159.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))